(Q36632128)

15 August 2017

1 reference

title

Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase (English)

1 reference

15 August 2017

2

Fatih M Uckun

1 reference

15 August 2017

Osmond J D'Cruz

1

1 reference

15 August 2017

language of work or name

1 reference

1 August 2006

1 reference

Journal of Enzyme Inhibition and Medicinal Chemistry

15 August 2017

published in

1 reference

15 August 2017

volume

21

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

329-350

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Declining AIDS mortality in Amsterdam: contributions of declining HIV incidence and effective therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Meeting the immense need for HAART in resource-poor settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Antiviral drugs in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

21 January 2018

New antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

A trial of three antiretroviral regimens in HIV-1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Novel derivatives of phenethyl-5-bromopyridylthiourea and dihydroalkoxybenzyloxopyrimidine are dual-function spermicides with potent anti-human immunodeficiency virus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Novel thiourea compounds as dual-function microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Conceival, a novel noncontraceptive vaginal vehicle for lipophilic microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

N-[2-(4-methylphenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea as a potent inhibitor of NNRTI-resistant and multidrug-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea compounds with potent anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

High resolution structures of HIV-1 RT from four RT-inhibitor complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Conformational analysis of the HIV-1 virus reverse transcriptase nonnucleoside inhibitors: TIBO and nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Structural requirements for potent anti-human immunodeficiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Stereochemistry as a major determinant of the anti-HIV activity of chiral naphthyl thiourea compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-240) with an analytical HPLC method

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

A 13-week subchronic intravaginal toxicity study of the novel broad-spectrum anti-HIV and spermicidal agent, N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (PHI-346) in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

Dawn of non-nucleoside inhibitor-based anti-HIV microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360600774413

10.1080/14756360600774413

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference